Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

von Hippel-Lindau Disease 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lung Neoplasms 1Kidney Neoplasms 1Hodgkin Disease 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Medullary 1Breast Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Paclitaxel 22Carboplatin 18liposomal doxorubicin 14Bevacizumab 9Topotecan 8Docetaxel 8Gemcitabine 7Cisplatin 7rucaparib 6pembrolizumab 6mirvetuximab soravtansine 5Cyclophosphamide 5Taxes 4Albumin-Bound Paclitaxel 4sargramostim 3ixabepilone 3Cytoreduction Surgical Procedures 3CCV-AV protocol 3130-nm albumin-bound paclitaxel 3taxane 2talazoparib 2pazopanib 2olaparib 2fludarabine phosphate 2fludarabine 2denileukin diftitox 2cediranib 2catumaxomab 2belinostat 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Ovarian Epithelial × tanespimycin × Clear all
NCT00093496 2014-05-20

Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2 Completed
29 enrolled 9 charts
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡